Background: Influenza is a contagious viral infection causing substantial morbidity and mortality. While vaccination considered the most effective means to prevent influenza morbidity, its effectiveness varies yearly depending on the circulating influenza strains. Seasonal surveillance in Israel in outpatient clinics allows the identification of the circulating influenza strains. Similar surveillance was performed in Europe and USA, (conducted by ECDC (European Center for Disease Control) and CDC (Center for Disease Control)).
Methods: Nasopharyngeal swabs collected from patients with influenza-like illness visiting dozens outpatient clinics in Israel (n=1487) and patients hospitalized in Sheba Medical Center (n=7310) between October-2018 and March-2019 were tested for influenza viruses. Data from this surveillance was compared to the data found in the ECDC, CDC and WHO websites.
Results and Conclusions: In 2018-19 winter, the dominant influenza virus in Israel was A/H3N2, while in Europe and USA, the dominant influenza virus was A/H1N1pdm09 for most of the winter that then changed to A/H3N2. Phylogenetic analysis indicated that the circulating Israeli A/H3N2 belonged to clade-3C.3a, while the vaccine strain, A/Singapore/INFIMH-16-0019/2016-(H3N2)-like-virus, belonged to clade-3C.2a1. Surprisingly, the European and USA A/H3N2 viruses mostly belonged to clade-3C.2a1 at the beginning of the winter, but shifted to clade 3C.3a in the middle of the winter.
The widespread distribution of different subtypes and clades of influenza A/H3N2 during a single season in highlights the need for the development of a universal influenza vaccine matching all virus subtypes, regardless of their genetic changes.